ReviewProbiotics and antimicrobial proteins2026
Microencapsulation of Limosilactobacillus reuteri and its Cell-Free Supernatant: Effects of Alginate-Enriched Wall Materials on Stability, Metabolite Profile, and Antimicrobial Activity.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluated the impact of spray-drying microencapsulation on the stability, metabolite profile, and antimicrobial activity of Limosilactobacillus reuteri ATCC 55,730 and its cell-free supernatant (CFS), using whey protein isolate (WPI) and maltodextrin (MD) with or without alginate (ALG) enrichment. The influence of selected prebiotics (alginate, inulin, and trehalose) on bacterial growth was also assessed. Alginate supplementation significantly enhanced bacterial growth, improved microcapsule structural integrity, and increased probiotic viability following spray drying and during storage. Organic acid analysis revealed lactic and acetic acids as the dominant metabolites, while GC-MS profiling demonstrated acetic acid as the principal volatile compound (up to 83%), accompanied by aldehydes, alcohols, hydrocarbons, and organic acid/amine derivatives. Following spray drying, the encapsulation efficiency of Lmb. reuteri was 70.85% for R1 (WPI-MD) and 73.02% for R2 (WPI-MD-ALG). Under simulated gastric conditions (pH 2.0, 120 min), the alginate-enriched formulation (R2) retained significantly higher viability (5.28 log CFU/mL) than the WPI-MD formulation without alginate (R1), which decreased to 4.46 log CFU/mL (p < 0.05). After simulated intestinal exposure, viable cell counts decreased to 4.92 and 3.96 log CFU/mL for R2 and R1, respectively, indicating greater viability retention in the alginate-enriched formulation. Additionally, Lmb. reuteri and its CFS exhibited antimicrobial activity against Lactococcus garvieae and Yersinia ruckeri, with the highest inhibition zone observed for the RS2 formulation against L. garvieae (28.67 mm). These findings indicate that alginate-assisted microencapsulation can improve probiotic viability and influence antimicrobial activity depending on the target pathogen and formulation, highlighting its potential as a natural bioactive system for food preservation and aquaculture applications.
Indexed as
Identifiers
42905337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.